News-Medical.Net on MSN1d
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...
Becker's Hospital Review2d
Rybelsus reduces cardiovascular event risk in late stage trial: Study
Novo Nordisk’s diabetes pill Rybelsus, an oral semaglutide, reduced the risk of major heart-related events by 14% in adults with Type 2 diabetes and cardiovascular disease or chronic kidney disease, ...
Fierce Pharma2d
FDA reviews Novo Nordisk's bid to expand Rybelsus as oral GLP-1 cuts heart disease risks
Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...
Managed Healthcare Executive4d
Rybelsus Reduces Cardiovascular Risk by 14% in New Trial | ACC 2025
Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults ...
BioSpace2d
Novo Paints ‘Complicated’ Cardio Picture for Semaglutide Franchise
According to BMO Capital Markets, Rybelsus’ outcomes in SOUL were “inconsistent,” failing to significantly lower ...
Pharmabiz1d
Novo Nordisk presents positive results from SOUL cardiovascular outcomes trial of Rybelsus at ACC’s annual scientific session
Bagsværd, Denmark Tuesday, April 1, 2025, 18:00 Hrs [IST] ...
Yahoo Finance4d
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Rybelsus ® reduced major adverse cardiovascular ... stroke and CV death in those treated with oral semaglutide vs placebo. The proven cardiovascular benefit reflects a profound clinical impact ...
PipelineReview.com3d
Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
BAGSVAERD, Denmark I March 29, 2025 I Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® ...
Mena FN4d
Novo Nordisk A/S: Rybelsus® (Oral Semaglutide 14 Mg) Demonstrates Superior Reduction In Cardiovascular Events In The SOUL Trial At ACC 2025
Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide) significantly ...
Finanznachrichten4d
Novo Nordisk A/S: Rybelsus (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
in the Rybelsus ® and placebo arms 1. In a key secondary analysis from SOUL published simultaneously, oral semaglutide reduced risk of MACE independently of baseline use of SGLT2i and suggests ...